Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
|
|
- Eleanor Dawson
- 5 years ago
- Views:
Transcription
1 Emerging Treatments and Technologies O R I G I N A L A R T I C L E Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy A randomized double-blind crossover study KASPER ROSSING, MD PER K. CHRISTENSEN, MD BERIT R. JENSEN HANS-HENRIK PARVING, PROF., MD, DMSC OBJECTIVE Many patients with diabetic nephropathy (DN) have levels of albuminuria 1 g/day and blood pressure 135/85 mmhg, despite antihypertensive combination therapy, including recommended doses of ACE inhibitors, e.g., lisinopril/enalapril at 20 mg daily. We tested the concept that such patients might benefit from dual blockade of the renin-angiotensin system (RAS). RESEARCH DESIGN AND METHODS We performed a randomized double-blind crossover study of 2 months treatment with candesartan cilexetil 8 mg once daily and placebo in addition to previous antihypertensive treatment. We included 18 type 2 diabetic patients with DN fulfilling the above-mentioned criteria. All received recommended doses of ACE inhibitor and, in addition, 15 patients received diuretics, 11 received a calcium channel antagonist, and 3 received a -blocker. At the end of each treatment period, we measured the glomerular filtration rate (GFR), 24-h blood pressure, albuminuria, and IgGuria. RESULTS The addition of candesartan to usual antihypertensive therapy induced a mean (95% CI) reduction in albuminuria of 25% (2 58), P (geometric mean [95% CI] from 1,764 mg/24 h [1,225 2,540] to 1,334 mg/24 h [890 1,998]). It also produced a mean reduction of 35% (9 53) in the fractional clearance of albumin (P 0.016), a reduction of 32% (1 54) in fractional clearance of IgG (P 0.046), a reduction in 24-h systolic blood pressure of 10 mmhg (2 18) (P 0.019) (mean SE) from 148 3to138 5 mmhg, and a mean reduction in GFR of 5 ml min m 2 (0.1 9) (P 0.045). CONCLUSIONS Dual blockade of the RAS reduces albuminuria and blood pressure in type 2 diabetic patients with DN responding insufficiently to previous antihypertensive therapy, including ACE inhibitors in recommended doses. Diabetes Care 25:95 100, 2002 Diabetic nephropathy (DN) occurs in 30% of all patients with diabetes and has become the leading cause of end-stage renal disease in the Western world (1). It is characterized by persistent albuminuria, elevated blood pressure, a relentless decline in the glomerular filtration rate (GFR), and a high risk for cardiovascular morbidity and mortality (1). The beneficial effect of blocking the renin-angiotensin system (RAS) by ACE inhibitors is well documented in DN. ACE inhibitors reduce arterial blood pressure, albuminuria, and the loss of kidney From the Steno Diabetes Center, Gentofte, Denmark. Address correspondence and reprint requests to Kasper Rossing, Steno Diabetes Center, Niels Steensens Vej 2, Dk-2820 Gentofte, Denmark. krossing@dadlnet.dk. Received for publication 20 June 2001 and accepted in revised form 21 September H.-H.P. has received honoraria or consulting fees from Merck, AstraZeneca, BMS, Sanofi-Synthelabo, and Pfizer, and he has received grant/research support from Merck and Sanofi-Synthelabo. Abbreviations: CALM, Candesartan and Lisinopril Microalbuminuria Study; DN, diabetic nephropathy; GFR, glomerular filtration rate; Alb, fractional clearance of albumin; IgG, fractional clearance of IgG; RAS, renin-angiotensin system; UKPDS, U.K. Prospective Diabetes Study. A table elsewhere in this issue shows conventional and Systéme International (SI) units and conversion factors for many substances. function and thereby postpone the uremic phase and increase survival (2 5). However, many patients with DN do not reach blood pressure targets and have persistently elevated albuminuria, despite treatment with several antihypertensive agents, including recommended doses of ACE inhibitors. The insufficient response might be explained by incomplete blockade of the RAS by either insufficient ACE inhibition due to underdosing, the socalled ACE-escape phenomenon (6), or by the generation of angiotensin II by ACE-independent pathways, such as chymase (7). A further effect might be obtained by combined therapy with both angiotensin receptor blockers and ACE inhibitors. By blocking the RAS at two different sites, a more complete inhibition might be obtained, and potential counter-regulatory responses will be diminished. The objective of our study was to evaluate the short-term effect of a dual blockade of the RAS by adding an angiotensin receptor blocker to the treatment of patients with DN responding insufficiently to previous antihypertensive treatment including ACE inhibitors in recommended doses. RESEARCH DESIGN AND METHODS Subjects At the Steno Diabetes Center, we recruited 18 type 2 diabetic patients (World Health Organization criteria) (8) with DN who had levels of albuminuria 1,000 mg/24 h as well as systolic blood pressure 135 mmhg and/or diastolic blood pressure 85 mmhg, despite antihypertensive combination therapy, including recommended doses of ACE inhibitor corresponding to 20 mg enalapril/lisinopril once daily or 100 mg captopril daily. DN was diagnosed clinically in patients with persistent albuminuria ( 300 mg/24 h), presence of diabetic retinopathy, and absence of any other clinical or laboratory evidence of other kidney or re- DIABETES CARE, VOLUME 25, NUMBER 1, JANUARY
2 Dual blockade in diabetic nephropathy of each treatment period. At the screening visit, albuminuria was determined in three 24-h urine samples, arterial blood pressure was measured three times after 10 min rest, and serum potassium and creatinine were determined. At 14 days after the beginning of each treatment period, blood pressure, serum potassium, and serum creatinine were measured for 14 days for safety reasons. At the end of each treatment period, we assessed clinical end points, including the primary end points albuminuria and 24-h arterial blood pressure and the secondary end point GFR. On the days of the kidney function studies, the patients met fasting at 8:00 A.M., blood samples were taken during the first hour, and then breakfast was given. Drug compliance was assessed by tablet counts. The local ethical committee approved the study, and all patients gave their informed consent to participate in the study after the nature of the study had been explained. Figure 1 Trial profile. A double-blind randomized crossover design evaluating the effects of adding candesartan cilexetil 8 mg daily or placebo to the treatment of type 2 diabetic patients with DN responding insufficiently to antihypertensive combination therapy, including recommended doses of ACE inhibitors. nal tract disease (9). A kidney biopsy was performed in patients lacking retinopathy, and only patients with diabetic glomerulopathy were enrolled in the trial. Exclusion criteria were: serum potassium 4.6 mmol/l, pregnancy, age 70 years, alcohol or medicine abuse, inability to understand the patient information, contra-indication to treatment with angiotensin receptor blocker, systolic blood pressure 100 mmhg, and GFR 25 ml/ min. Design We performed a randomized doubleblind crossover trial (Fig. 1). Each patient received in random order 2 months treatment with 8 mg candesartan cilexetil once daily and 2 months treatment with one matched placebo tablet daily. Randomization was in blocks of two with concealed computer-generated envelopes. The code was not broken until all data were entered in a database. The study medication was added to the patients previous antihypertensive treatment, which was left unchanged throughout the study and which included ACE inhibitors for all patients in daily doses corresponding to 20 mg lisinopril/enalapril or 100 mg captopril daily. None of the patients had their dietary intake of salt or protein restricted. Patients attended the clinic for a total of five study visits: one screening visit and then visits at 2 and 8 weeks after the start Methods GFR was measured after a single intravenous injection of 3.7 MBq 51 Cr-EDTA at 8:00 A.M. by determining the radioactivity in venous blood samples taken 180, 200, 220, and 240 min after the injection (10,11). Extra renal loss was accounted for by subtracting 3.7 ml/min (12). The small underestimation (10%) of 51 Cr- EDTA renal clearance versus renal clearance of inulin was corrected by multiplying the EDTA clearance by 1.10 (12). The results were standardized for 1.73 m 2 body surface area. The mean day-to-day coefficient of variation in GFR is 4% in our laboratory. Arterial blood pressure values were measured by 24-h ambulatory blood pressure measurements using a Takeda TM2420 device (A&D Medical, Tokyo). A measurement of the blood pressure was performed every 15 min in the time period from 7:00 A.M. to 11:00 P.M. and every 30 min from 11:00 P.M. to 7:00 A.M.To determine mean day- and night-time blood pressures, patients were asked what time they went to sleep and what time they woke up. Values were averaged for each hour before calculating the mean 24-h, day, and night arterial blood pressures. Albuminuria was determined as the geometric mean of three consecutive 24-h urine collections, completed immediately 96 DIABETES CARE, VOLUME 25, NUMBER 1, JANUARY 2002
3 Rossing and Associates Table 1 Results of 2 months additional treatment with candesartan cilexetil 8 mg daily in 17 type 2 diabetic patients with DN responding insufficiently to conventional antihypertensive treatment including recommended doses of ACE inhibitior Placebo Candesartan 8 mg daily Mean difference (95% CI) P Systolic blood pressure (mmhg) 24-h (2 18) Day (1 20) 0.03 Night (2 16) 0.01 Diastolic blood pressure (mmhg) 24-h ( 1 to 6) 0.17 Day ( 1 to 7) 0.19 Night ( 4 to 7) 0.63 Albuminuria (mg/24 h)* 1,764 (1,225 2,540) 1,334 (890 1,998) 24% (2 58) Alb ( 10 6 ) 476 ( ) 310 ( ) 35% (9 53) IgG ( 10 6 ) 124 (58 266) 84 (40 180) 32% (1 54) GFR (ml min m 2 ) (0.1 9) Serum creatinine ( mol/l) ( 5 to 15) 0.31 Serum potassium (mmol/l) ( 0.20 to 0.02) 0.09 HbA 1c (%) ( 0.04 to 0.3) 0.68 Serum angiotensin II (pmol/l) ( 4.1 to 13.2) 0.28 Urinary sodium (mmol/24 h) ( 43 to 30) 0.7 Data are means SE or means (95% CI). *Geometric mean (95% CI). before each visit at the end of each treatment period (using turbidimetry performed with a Cobas Mira Plus [Roche, Montclair, NJ]). During the clearance procedure, urine was collected quantitatively to determine albuminuria and Ig- Guria (using enzyme-linked immunosorbent assay) (13). In addition, sodium, urea, creatinine, and carbamid excretion in the urine were determined (Cobas Mira Plus; Roche). The excretion of urea was used to calculate the protein intake from the nitrogen content of the urea and an estimated value of nonurea nitrogen of 31 mg 1 kg 1 24 h 1 (14). To eliminate changes in albuminuria caused by variation in serum albumin and GFR, we determined the fractional clearance of albumin ( Alb ) and IgG ( IgG )as [urinary protein excretion]/([serum protein concentration] [GFR]). From venous samples, serum potassium, sodium, creatinine, and cholesterol concentrations were determined (BM/ Hitachi system; Boehringer Mannheim, Roche Laboratory Systems, Mannheim, Germany), and HbA 1c was measured by high-performance liquid chromatography (normal range %) (Variant; Biorad Laboratories). Blood samples for angiotensin II levels were drawn in prechilled tubes after 30 min supine rest and immediately centrifuged at 4 C. Plasma concentrations were measured radioimmunnologically (15). Statistical analysis Normally distributed variables are expressed as the mean SD and otherwise as median (range). Values for albuminuria, Alb, and IgG clearance were logarithmically transformed and are expressed as the geometric mean (95% CI) because of their positively skewed distribution. Changes in variables between visits are expressed as the mean (95% CI). All comparisons of normally or log normally distributed parameters were performed with a paired Student s t test. Data were tested for a period effect and a treatment-period interaction with a twosample t test. Before the present study, we calculated the SD (log scale ) of the mean difference in urinary albumin excretion rate in three consecutive 24-h urine samples collected twice within 3 months in 36 diabetic patients with DN. Based on these data, a sample-size calculation revealed a necessary minimum of 16 patients to detect a 25% difference in change in the urinary albumin excretion rate ( 0.05 and 0.8). The difference between the two examinations was transformed into absolute changes in arterial blood pressure and relative changes in albuminuria and GFR. Linear regression analysis was used to analyze for correlations between the change in arterial blood pressure and the relative change in GFR (%). Spearman s rank correlation was used to estimate the correlation between the change in arterial blood pressure and the change in albuminuria. P 0.05 was considered significant (two-tailed test). Data were evaluated using SPSS version 10.0 (SPSS, Chicago, IL). RESULTS One patient was excluded because he discontinued active treatment after 2 weeks because of nausea and stomach upset. No other adverse effects were reported. Altogether, 17 patients completed the study (Fig. 1). The median (range) duration of each treatment period was 63 days (57 74), and compliance as assessed by tablet count was 100% (95 100) during both placebo and candesartan treatment. We found no evidence of carryover or sequence effects in the treatment periods in the statistical analysis. At entry to the study, the mean ( SD) known duration of diabetes and DN was 13 6 and 8 5 years, respectively. The mean age of the patients was 58 8 years, 13 of 17 were male, and the mean BMI was 32 4 kg/m 2. Seven patients had nonproliferative diabetic retinopathy and six had proliferative diabetic retinopathy. Four patients showed no signs of diabetic retinopathy. In these patients, the diagnosis of diabetic glomerulopathy was verified by a renal biopsy. The patients suffered primarily isolated systolic hypertension, with a sitting office blood DIABETES CARE, VOLUME 25, NUMBER 1, JANUARY
4 Dual blockade in diabetic nephropathy pressure of mmhg systolic and a blood pressure of 85 7 mmhg diastolic, and all had highly elevated albuminuria, with a geometric mean (95%CI) of 1,781 mg/24 h (1,326 2,391), despite antihypertensive treatment. The median number of antihypertensive agents was 3 (range 2 4). All patients received ACE inhibitors in daily doses corresponding to 20 mg lisinopril and enalapril (n 5 and 9, respectively) or 100 mg captopril (n 4). In addition to ACE inhibition, nearly all patients received diuretics (n 15), 11 patients received a calcium channel antagonist (10 mg amlodipine once daily), and 3 were treated with a -blocker. Values for 24-h systolic blood pressure, albuminuria, Alb, IgG, and GFR were significantly lower during dual blockade of the RAS, when candesartan cilexetil 8 mg was added to conventional ACE inhibitor treatment, as compared with blockade using ACE inhibitors alone (Table 1). In 16 patients, 24-h recordings of the arterial blood pressure were available. In these patients, the mean difference (95%CI) for the 24-h systolic blood pressure decreased by 10 mmhg (2 18) during the addition of 8 mg candesartan cilexetil. The reduction in systolic blood pressure was sustained during both the day and night (Table 1). The decline in 24-h diastolic blood pressure of 3 mmhg ( 2 to 6) during candesartan treatment was not statistically significant, and no significant changes were found in the 24-h mean heart rate. Altogether, seven patients had a decline in 24-h systolic blood pressure of 10 mmhg. These patients were characterized by higher baseline (placebo) values for 24-h diastolic blood pressure (77 6 vs mmhg; P 0.011) and plasma angiotensin II levels ( vs pmol/l; P 0.02). There was a significant positive correlation between the level of angiotensin II during placebo treatment and the absolute decrease in arterial blood pressure during addition of candesartan (r 0.66; P 0.004). Albuminuria was reduced from placebo values by 25% (2 58) during dual blockade of the RAS. Alb Was reduced by 35% (9 58), and IgG was reduced by 32% (1 54). There was a significant correlation between changes in systolic blood pressure and albuminuria (correlation coefficient 0.53; P 0.03) (Fig. 2). Figure 2 Correlation between absolute reductions in 24-h systolic blood pressure (in mmhg) (placebo candesartan) and reduction in albuminuria (in log mg/24 h) (log placebo log candesartan) during addition of candesartan cilexetil 8 mg daily in 16 type 2 diabetic patients responding insufficiently to antihypertensive combination therapy. All received ACE inhibition corresponding to 20 mg enalapril (n 9)/lisinopril (n 5) and 100 mg captopril (n 4) daily. Symbols indicate the number of additional antihypertensive agents. f 1; F 2; Œ 3. All patients received diuretics except two ( ). GFR was reduced by 5 ml min m 2 (0.1 9) during the addition of candesartan treatment (P 0.05). The relative decline (in percent) in GFR during candesartan treatment was positively correlated with the decline in systolic blood pressure (r 0.58; P 0.01). Serum potassium, sodium, creatinine, HbA 1c, and angiotensin II remained unchanged, as did urinary sodium excretion (Table 1). CONCLUSIONS In our randomized double-blind crossover trial, we demonstrated that dual blockade of the RAS induced a reduction in 24-h systolic blood pressure, albuminuria, Alb, and IgG in type 2 diabetic patients with DN responding insufficiently to antihypertensive treatment including recommended dose of ACE inhibition. These beneficial effects were obtained despite a very high dietary intake of salt, a condition lowering the activity of the RAS and impairing the effect of agents blocking the synthesis and effects of angiotensin II. The therapy was well tolerated and safe, with no incidence of hyperkalaemia or hypotension. The safety of concomitant use of angiotensin receptor blockers and ACE inhibitors has also been documented in two multicenter studies that included patients with chronic renal disease (16) and those with type 2 diabetes and microalbuminuria (17). We found a slight decrease in GFR during treatment with candesartan. This is probably explained by the reduced blood pressure, and is most likely fully reversible when treatment is discontinued, as previously suggested (18). In patients who received candesartan in the first treatment period, the GFR increased by5ml min m 2 during subsequent treatment with placebo. This suggests a reversible effect of candesartan on GFR There was a great variability in the response to treatment. Three patients did not have a reduction in either blood pressure or albuminuria. Two of these patients did not receive diuretics, which are known to potentiate agents blocking the RAS. Conversely, seven patients had a 10 mmhg decline in 24-h systolic blood pressure. These patients were characterized by higher baseline (placebo) values of diastolic blood pressure and plasma angiotensin II levels as compared with the rest of the patients. The additional effect obtained by dual blockade in our study indicates an incomplete inhibition of the RAS during ACE inhibitor treatment. This may be caused by underdosing of the ACE inhibitor or the ACE-escape phenomenon (6), or it may reflect a true additive effect of dual blockade. In the present study, patients received doses of ACE inhibition equal to or higher than that previously used in 98 DIABETES CARE, VOLUME 25, NUMBER 1, JANUARY 2002
5 Rossing and Associates long-term studies documenting a renoprotective effect in DN (2 5,19,20). The dose of 20 mg lisinopril/enalapril corresponds to the dose inducing the maximal blood pressure lowering effect in patients with moderate-to-severe essential hypertension (21 24). In these trials no additional significant reduction in blood pressure was demonstrated, despite a dose escalation of enalapril/lisinopril to 80 mg daily or an increase of captopril to 600 mg daily (21). A true additive effect of dual blockade on blood pressure is suggested by our finding of a significant reduction in systolic blood pressure. The optimal dose of ACE inhibitors with respect to a maximal reduction in albuminuria has never been established in Caucasian patients with DN. However, recently it was reported that the addition of 50 mg losartan daily to a regimen of 40 mg lisinopril daily had no additional effect on arterial blood pressure and proteinuria in a small group of hypertensive proteinuric African-Americans with advanced renal failure of different origin (25). Surprisingly, this study showed a lowered plasma renin activity and enhanced GFR during treatment with 50 mg losartan daily. Nevertheless, these findings cannot be extrapolated to other ethnic groups because suppressed RAS activity and reduced effect of blocking the action/formation of angiotensin II have been demonstrated in African Americans suffering from DN (26) or left ventricular dysfunction (27). Consequently, future studies in Caucasians must evaluate whether additional effects on albuminuria can be obtained with increased doses of ACE inhibition (e.g., 40 mg enalapril/lisinopril daily). Within recommended doses, ACE inhibitors and angiotensin receptor blockers are equally effective in reducing blood pressure and albuminuria (17,28). Consequently, the results in our study could probably not be obtained simply by substituting the ACE inhibitor with an angiotensin II receptor antagonist. Our patients received equipotent doses of different types of ACE inhibitors (29). The Candesartan and Lisinopril Microalbuminuria (CALM) study, which included patients with type 2 diabetes, microalbuminuria, and hypertension, demonstrated an enhanced reduction in blood pressure by dual blockade (16 mg candesartan cilexetil and 20 mg lisinopril) compared with therapy with either agent alone (17). The reduction obtained in sitting systolic blood pressure on monotherapy using either drug alone was 15 mmhg. The additional effect of combination therapy was a further reduction in systolic blood pressure of 10 mmhg corresponding to the decrease obtained in our study. In the CALM study, there was a tendency for a more pronounced antiproteinuric effect of dual blockade, as documented in our study dealing with overt DN. Albuminuria and hypertension are strong predictors of poor renal and cardiovascular outcome in diabetic patients, and numerous studies have demonstrated that by reducing these risk factors, antihypertensive treatment slows the progression of DN, as reviewed by Parving (30). Furthermore, the magnitude of the initial reduction in albuminuria induced by the initiation of ACE inhibitor treatment has been shown to predict the long-term rate of decline in GFR in the succeeding years, i.e., the greater the reduction in proteinuria, the less the decline in kidney function (31 33). Consequently, the short-term reduction in albuminuria demonstrated in the present study during dual blockade may suggest a long-term renoprotective effect of such a treatment strategy. The long-term renoprotective effect of dual blockade of the RAS remains to be established. However, recent studies (26,34) with angiotensin II receptor antagonists suggest a progressive beneficial effect on urinary albumin excretion as compared with conventional antihypertensive treatment in micro- and macroalbuminuric type 2 diabetic patients. Furthermore, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study documented a greater beneficial effect of angiotensin II receptor antagonists as compared with conventional antihypertensive agents on the combined end point of doubling of baseline serum creatinine, end-stage renal disease, or death in type 2 patients with diabetes and proteinuria (26). This additional renoprotective effect of the receptor antagonists was obtained with nearly identical blood pressure levels. The correlation between blood pressure and albuminuria found in our study has been demonstrated in several other studies, as reviewed by Parving (30). The correlation suggests that the renoprotective effect is due at least in part to changes in systemic and local hemodynamics, with a reduction in glomerular capillary hydraulic pressure. The reduction in albuminuria might also be attributable to structural changes such as improved size-selective properties of the glomerular capillary membrane, as demonstrated in patients with type 1 diabetes (35). Our study did not suggest such a mechanism because the reduction in fractional clearance of the larger molecule IgG paralleled the reduction in fractional clearance of albumin. In the U.K. Prospective Diabetes Study (UKPDS), tight blood pressure control led to a reduction in arterial blood pressure of 10 mmhg systolic and 5 mmhg diastolic when compared with less tight control. This blood pressure reduction was associated with a risk reduction of 32% in deaths related to diabetes, 37% in microvascular complications, 44% in stroke, and 56% in heart failure (36). The reduction in blood pressure was 10 mmhg systolic and 3 mmhg diastolic in our long-standing complicated type 2 diabetic patients with DN. Because the absolute risk of cardiovascular events is much higher in our patients than in the UKPDS study, such patients may benefit even more if the blood pressure reduction can be sustained for years. In conclusion, dual blockade of the RAS is well tolerated and reduces albuminuria and blood pressure in patients with type 2 diabetes and DN responding insufficiently to antihypertensive combination therapy, including the recommended dose of ACE inhibitor. However, the long-term renoprotective effects remain to be evaluated. Acknowledgments This study was supported by a grant from AstraZeneca. The authors thank Tina R. Juhl, Ulla M. Scmidt, Birgitte V. Hansen, and Inge-Lise Rossing for laboratory assistance and Peter Rossing for statistical assistance. References 1. Parving H-H, Østerby R, Ritz E: Diabetic nephropathy. In The Kidney. 6th ed. Brenner BM, Levine S, Eds. Philadelphia, WB Saunders, 2000, p Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica D, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, Bolten WK: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 45 DIABETES CARE, VOLUME 25, NUMBER 1, JANUARY
6 Dual blockade in diabetic nephropathy (Suppl. 45):S150 S155, Bakris GL: Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 112: , Nielsen FS, Rossing P, Gall M-A, Skøtt P, Smidt UM, Parving H-H: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46: , Fogari R, Zoppi A, Corradi L, Mugellini A, Lazzari P, Preti P, Lusardi P: Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 13:47 53, Nussberger J, Brunner DB, Waeber B, Brunner HR: Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans. J Hypertens Suppl 3 (Suppl. 3):S269 S270, Hollenberg NK, Fisher NDL, Price DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 32: , World Health Organization: Diabetes Mellitus, Report of a WHO Study Group. Geneva, World Health Org., Parving H-H, Gall M-A, Skøtt P, Jørgensen HE, Løkkegaard H, Jørgensen F, Nielsen B, Larsen S: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41: , Bröchner-Mortensen J, Rödbro P: Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36:35 45, Bröchner-Mortensen J: A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30: , Bröchner-Mortensen J, Rödbro P: Comparison between total and renal plasma clearance of [ 51 Cr]EDTA. Scand J Clin Lab Invest 36: , Fomsgaard A, Feldt-Rasmussen B, Deckert M, Dinesen B: Micro-ELISA for the quantitation of human urinary IgG: technical note. Scand J Clin Lab Invest 47: , Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27:58 65, Kappelgaard AM, Nielsen MD, Giese J: Measurement of angiotensin II in human plasma: technical modifications and practical experience. Clin Chim Acta 67: , Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF: Safety of the combination of valsartan and benazepril in patients with chronic renal disease: European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18:89 95, Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 321: , Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving H-H: Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 47: , Hommel E, Parving H-H, Mathiesen ER, Edsberg B, Nielsen MD, Giese J: Effect of captopril on kidney function in insulindependent diabetic patients with nephropathy. Br Med J 293: , Lewis E, Hunsicker L, Bain R, Rhode R: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: , Gomez HJ, Cirillo VJ, Sromovsky JA, Otterbein ES, Shaw WC, Rush JE, Chrysant SG, Gradman AH, Leon AS, MacCarthy EP, Nelson EB, Pool J, Vedin A: Lisinopril dose-response relationship in essential hypertension. Br J Clin Pharmacol 28: , Sassano P, Chatellier G, Billaud E, Corvol P, Menard J: Comparison of increase in the enalapril dose and addition of hydrochlorothiazide as second-step treatment of hypertensive patients not controlled by enalapril alone. J Cardiovasc Pharmacol 13: , Lijnen P, Fagard R, Staessen J, Verschueren LJ, Amery A: Dose response in captopril therapy of hypertension. Clin Pharmacol Ther 28: , Eber B, Brussee H, Rotman B, Kramer R, Klein W: Evaluation of the antihypertensive effect of lisinopril compared with nifedipine in patients with mild to severe essential hypertension. Angiology 43: , Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 59: , Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: , Exner DV, Dries DL, Domanski MJ, Cohn JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344: , Andersen S, Tarnow L, Rossing P, Hansen BV, Parving H-H: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57: , Verme-Gibboney C: Oral angiotensinconverting-enzyme inhibitors. Am J Health Syst Pharm 54: , Parving H-H: Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 41: , Rossing P, Hommel E, Smidt UM, Parving H-H: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 45:S145 S149, Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38: , Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensive treatment predicts longterm GFR decline in patients with nondiabetic renal disease. Kidney Int Suppl 45: S174 S178, Parving H-H, Lehnert H, Bröchner- Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD: Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 58: , UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317: , DIABETES CARE, VOLUME 25, NUMBER 1, JANUARY 2002
The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence?
Reviews ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence? George L. Bakris, MD; 1 and Matthew Weir, MD 2 Although angiotensin-converting
More informationDiabetic nephropathy occurs in 30
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Renoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy A
More informationAdditive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy
J Am Soc Nephrol 14: 992 999, 2003 Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy PETER JACOBSEN,* STEEN ANDERSEN,* BERIT R.
More informationRenal Protection Staying on Target
Update Staying on Target James Barton, MD, FRCPC As presented at the University of Saskatchewan's Management of Diabetes & Its Complications (May 2004) Gwen s case Gwen, 49, asks you to take on her primary
More informationDiabetes Care 23: , 2000
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Long-Term Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Patients With Diabetic Nephropathy LISE TARNOW, MD PETER
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationDiabetes has become the most common
P O S I T I O N S T A T E M E N T Diabetic Nephropathy AMERICAN DIABETES ASSOCIATION Diabetes has become the most common single cause of end-stage renal disease (ESRD) in the U.S. and Europe; this is due
More informationDiabetes has become the most common
P O S I T I O N S T A T E M E N T Diabetic Nephropathy AMERICAN DIABETES ASSOCIATION Diabetes has become the most common single cause of end-stage renal disease (ESRD) in the U.S. and Europe; this is due
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationAn acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
original article http://www.kidney-international.org & 2011 International Society of Nephrology see commentary on page 235 An acute fall in estimated glomerular filtration rate during treatment with losartan
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN TYPE I DIABETIC NEPHROPATHY DR.NASIM MUSA
ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN TYPE I DIABETIC NEPHROPATHY DR.NASIM MUSA Type I IDDM is characterized by The abrupt onset of symptoms Insulinopenia
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationTubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy
http://www.kidney-international.org & 2011 International Society of Nephrology original article see commentary on page 1042 Tubular markers do not predict the decline in glomerular filtration rate in type
More informationLong-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Long-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes The CALM II study NIELS H. ANDERSEN, MD, PHD
More informationDual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy
Kidney International, Vol. 63 (2003), pp. 1874 1880 Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy PETER JACOBSEN, STEEN ANDERSEN,
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationNephrology. Safety and Tolerability of High-Dose Angiotensin Receptor Blocker Therapy in Patients with Chronic Kidney Disease: A Pilot Study
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Am J Nephrol 2004;24:340 345 DOI: 10.1159/000078950 Received: March 8, 2004 Accepted: April 5, 2004 Published online:
More informationRenal protection by inhibition of the renin-angiotensinaldosterone
Renal protection by inhibition of the renin-angiotensinaldosterone system Tomas Berl Key words: angiotensinconverting enzyme inhibitor, angiotensin receptor blocker, combination therapy, direct renin inhibitor,
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationAngiotensin-converting enzyme inhibitors (ACEI) and
Are Two Better Than One? Angiotensin-Converting Enzyme Inhibitors Plus Angiotensin Receptor Blockers for Reducing Blood Pressure and Proteinuria in Kidney Disease Stuart L. Linas Department of Internal
More informationProteinuria increases the risk for progression of chronic. Review
Review Annals of Internal Medicine Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin Angiotensin System on Proteinuria in Renal Disease Regina Kunz, MD, MSc(Epi);
More informationThe retinal renin-angiotensin system: implications for therapy in diabetic retinopathy
(2002) 16, S42 S46 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh : implications for therapy in diabetic retinopathy AK Sjølie 1 and N Chaturvedi 2 1 Department
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Antihypertensive therapy in diabetic nephropathy GUIDELINES
Antihypertensive therapy in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Adequate control of blood pressure (BP) slows progression
More informationConclusion: Dual blockade of the RAAS is safe. and effective in reducing albuminuria in Asian. type 2 diabetic patients with nephropathy.
Original Article Singapore Med J 201 0; 51(2) : 1 51 Dual blockade of the renin-angiotensinaldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers PROTEINURIA
More informationAcute Effects of Different Intensities of Exercise in Normoalbuminuric/ Normotensive Patients With Type 1 Diabetes
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Acute Effects of Different Intensities of Exercise in Normoalbuminuric/ Normotensive Patients With Type 1 Diabetes JAMES T. LANE, MD 1 TIMOTHY
More informationC URRENT T HERAPEUTIC R ESEARCH. 94 Copyright 2007 Excerpta Medica, Inc. Reproduction in whole or part is not permitted.
C URRENT T HERAPEUTIC R ESEARCH V OLUME 68, NUMBER 2, MARCH/APRIL 27 Anti-Albuminuric Effect of Losartan Versus Amlodipine in Hypertensive Japanese Patients with Type 2 Diabetes Mellitus: A Prospective,
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationNew Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
More informationPregnancy and progression of diabetic nephropathy
Diabetologia 2002) 45: 36±41 Ó Springer-Verlag 2002 Articles Pregnancy and progression of diabetic nephropathy K. Rossing, P. Jacobsen, E. Hommel, E. Mathiesen, A. Svenningsen, P. Rossing, H-H. Parving
More informationAccording to the US Renal Data System,
DIABETIC NEPHROPATHY * Mohamed G. Atta, MD ABSTRACT *Based on a presentation given by Dr Atta at a CME dinner symposium for family physicians. Assistant Professor of Medicine, Division of Nephrology, Johns
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationAutoregulation of Glomerular Filtration Rate in Patients With Type 2 Diabetes During Isradipine Therapy
Pathophysiology/Complications O R I G I N A L A R T I C L E Autoregulation of Glomerular Filtration Rate in Patients With Type 2 Diabetes During Isradipine Therapy PER K. CHRISTENSEN, MD 1 KAMRAN AKRAM,
More informationHTN: 80 mg once daily 23,f 80 mg once daily 23,f Hypertension 40, 80 mg $82.66 (80 mg once daily) HTN: 8-32 mg daily in one or two divided doses 1
Detail-Document #260301 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2010 ~ Volume 26 ~ Number 260301 Comparison of Angiotensin Receptor
More informationPapers. Abstract. Participants and methods. Introduction
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationEffect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial
Int Urol Nephrol (2012) 44:1763 1770 DOI 10.1007/s11255-011-0110-z NEPHROLOGY ORIGINAL PAPER Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised,
More informationManagement of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Review Advances in CKD 216 Published online: January 15, 216 Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Hillel Sternlicht George L. Bakris Department of Medicine, Section
More informationDiabetologia 9 Springer-Verlag 1981
Diabetologia (1981) 20:457-461 Diabetologia 9 Springer-Verlag 1981 A Prospective Study of Glomerular Filtration Rate and Arterial Blood Pressure in Insulin-Dependent Diabetics with Diabetic Nephropathy
More informationRemission and Regression of Diabetic Nephropathy
515 Review Remission and Regression of Diabetic Nephropathy Hirofumi MAKINO, Yoshio NAKAMURA, and Jun WADA Diabetic nephropathy has become the single largest cause of end-stage renal disease (ESRD) worldwide.
More informationTread Carefully Because you Tread on my Nephrons. Prescribing Hints in Renal Disease
Tread Carefully Because you Tread on my Nephrons Prescribing Hints in Renal Disease David WP Lappin,, MB PhD FRCPI Clinical Lecturer in Medicine and Consultant Nephrologist and General Physician, Merlin
More informationTherapeutic approaches to slowing the progression of diabetic nephropathy is less best?
www.drugsincontext.com The journal of interventions in clinical practice REVIEW Therapeutic approaches to slowing the progression of diabetic nephropathy is less best? FULL TEXT ARTICLE Eva Vivian, 1 Chelsea
More informationLow-Dose Candesartan Cilexetil Prevents Early Kidney Damage in Type 2 Diabetic Patients with Mildly Elevated Blood Pressure
453 Original Article Low-Dose Candesartan Cilexetil Prevents Early Kidney Damage in Type 2 Diabetic Patients with Mildly Elevated Blood Pressure Satoru MURAYAMA, Tsutomu HIRANO, Taro SAKAUE, Kenta OKADA,
More informationHypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease
Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease July 2017 Indranil Dasgupta DM FRCP, Debasish Banerjee MD
More informationRisk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study
Indian J Med Res 136, July 2012, pp 46-53 Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study Vijay Viswanathan, Priyanka Tilak
More informationACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD )
005 16 175-180 1 1 ( chronic kidney disease, CKD ) 003 ( end-stage renal disease, ESRD ) Angiotensin-converting enzyme inhibitors ( ) angiotensin receptor blockers ( ) nondihydropyridine ( NDHP ) / NDHP
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationThe hypertensive kidney and its Management
The hypertensive kidney and its Management Dr H0 Chung Ping Hypertension Management Seminar 20061124 Hypertensive kidney Kidney damage asymptomatic till late stage Viscous cycle to augment renal damage
More informationCommonKnowledge. Pacific University. Holly A. Walkington Pacific University
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects 8-14-2010 Effects of Dual Blockade of the ReninAngiotensin System Compared to Single
More informationComparison between the efficacy of double blockade and single blockade of RAAS in diabetic kidney disease
International Journal of Advances in Medicine Gupta A et al. Int J Adv Med. 2018 Aug;5(4):931-935 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20183122
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationAnalysis of Factors Causing Hyperkalemia
ORIGINAL ARTICLE Analysis of Factors Causing Hyperkalemia Kenmei Takaichi 1, Fumi Takemoto 1, Yoshifumi Ubara 1 and Yasumichi Mori 2 Abstract Objective Patients with impaired renal function or diabetes
More informationThe control of hypertension in the. Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy REPORTS
REPORTS Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy By Richard V. Milani, MD Abstract Elevated blood pressure, particularly systolic blood
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor Treatment in Diabetic Nephropathy GUIDELINES
ACE Inhibitor Treatment in Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All patients with Type 1 or Type 2 diabetes mellitus complicated
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationFan Shunan 1, Yuan Jiqing 2 and Dong Xue 3. Introduction. Original Article
803495JRA0010.1177/1470320318803495Journal of the Renin Angiotensin Aldosterone SystemShunan et al. research-article20182018 Original Article Effects of angiotensin-converting enzyme inhibitors and angiotensin
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationVA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease
VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERECE CARDS Chronic Kidney Disease CKD VA/DoD Clinical Practice Guideline for the Management
More informationRenal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria
Diabetologia (1996) 39: 1611 1616 Springer-Verlag 1996 Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria Ch. Schnack, W. Hoffmann, P. Hopmeier,
More informationKeywords albuminuria, hypertension, nephropathy, proteinuria
Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Rigas G. Kalaitzidis and George L. Bakris Department of Medicine, Hypertensive Diseases
More informationLong-Term Renoprotective Effects of Losartan in Diabetic Nephropathy. Interaction with ACE insertion/deletion genotype?
Pathophysiology/Complications O R I G I N A L A R T I C L E Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy Interaction with ACE insertion/deletion genotype? STEEN ANDERSEN, MD 1 LISE
More informationLaunch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
More informationGlomerular size- and charge selectivity in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy
Diabetologia (1994) 37:195-21 Springer-Verlag 1994 Glomerular size- and charge selectivity in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy M.-A. Gall, P. Rossing, A. Kofoed-Enevoldsen,
More informationHypertension and diabetes are the most. Diabetes and Hypertension: Blood Pressure Control and Consequences Matthew R. Weir
AJH 1999;12:170S 178S Diabetes and Hypertension: Blood Pressure Control and Consequences Matthew R. Weir Diabetes and hypertension are the leading causes of end-stage renal disease in the Western world.
More informationHigher levels of Urinary Albumin Excretion within the Normal Range Predict Faster Decline in Glomerular Filtration Rate in Diabetic Patients
Diabetes Care Publish Ahead of Print, published online May 12, 2009 Albuminuria and GFR Decline in Diabetes Higher levels of Urinary Albumin Excretion within the Normal Range Predict Faster Decline in
More informationDiabetes is the most common cause of end-stage renal
Pharmacoeconomic Challenges in the Management of Diabetic Nephropathy ROGER A. RODBY, MD ABSTRACT BACKGROUND: Diabetes is the most common cause of end-stage renal disease (ESRD) kidney failure to the point
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationEFFICACY OF ANTI-HYPERTENSIVE IN PROLONGING DIABETIC NEPHROPATHY
IJRPC 8, 8(), -6 Narender et al ISSN: 78 INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article EFFICACY OF ANTI-HYPERTENSIVE IN PROLONGING DIABETIC
More informationDiabetic nephropathy develops in
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors,
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationPeggy Roestenberg - The role of CTGF in diabetic nephropathy
Peggy Roestenberg - The role of CTGF in diabetic nephropathy Chapter 4 Plasma levels of connective tissue growth factor correlate with clinical markers of renal disease in type 1 diabetic patients with
More informationSodium Sensitivity Related to Albuminuria Appearing Before Hypertension in Type 2 Diabetic Patients
Pathophysiology/Complications O R I G I N A L A R T I C L E Sodium Sensitivity Related to Albuminuria Appearing Before Hypertension in Type 2 Diabetic Patients MASAHITO IMANISHI, MD KATSUNOBU YOSHIOKA,
More informationChronic Kidney Disease Management for Primary Care Physicians. Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015
Chronic Kidney Disease Management for Primary Care Physicians Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015 Singapore Renal Registry 2012 Incidence of Patients on Dialysis by Mode of Dialysis
More informationDiuretic uptitration with half dose combined ACEI + ARB better decrease proteinuria than combined ACEI + ARB uptitration
Nephrol Dial Transplant (2010) 25: 22 2224 doi: 10.1093/ndt/gfp776 Advance Access publication 26 January 2010 Diuretic uptitration with half dose combined ACEI + ARB better decrease proteinuria than combined
More informationDiabetes Care 29: , 2006
Pathophysiology/Complications O R I G I N A L A R T I C L E Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left
More informationThe hypertensive effects of the renin-angiotensin
Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationThe Ramipril Efficacy in Nephropathy (REIN) study was
Add-On Angiotensin Receptor Blocker in Patients Who Have Proteinuric Chronic Kidney Diseases and Are Treated with Angiotensin-Converting Enzyme Inhibitors Yoshihiko Kanno,* Tsuneo Takenaka,* Tsukasa Nakamura,
More informationThe Seventh Report of the Joint National Commission
The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationCLINICIAN INTERVIEW A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY. Interview with Ralph Rabkin, MD
A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY Interview with Ralph Rabkin, MD Dr Rabkin is Professor of Medicine, Emeritus, Active, at Stanford University School of Medicine, Stanford,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationPlasma aldosterone concentration in the patient with diabetes mellitus Rapid Communication
Kidney International, Vol. 65 (2004), pp. 1435 1439 Plasma aldosterone concentration in the patient with diabetes mellitus Rapid Communication NORMAN K. HOLLENBERG, RADOMIR STEVANOVIC, ANUPAM AGARWAL,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 392 151-6) RASILEZ HCT 150 mg/25 mg, film-coated
More informationIncreased Risk of Renal Deterioration Associated with Low e-gfr in Type 2 Diabetes Mellitus Only in Albuminuric Subjects
ORIGINAL ARTICLE Increased Risk of Renal Deterioration Associated with Low e-gfr in Type 2 Diabetes Mellitus Only in Albuminuric Subjects Shu Meguro, Toshikatsu Shigihara, Yusuke Kabeya, Masuomi Tomita
More informationPhase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018
Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,
More informationHypertension is a major risk factor for
OPTIMAL RISK MANAGEMENT OF THE HYPERTENSIVE PATIENT WITH MULTIPLE RISK FACTORS * Keith C. Ferdinand, MD, FACC ABSTRACT To determine the risk of cardiovascular disease in patients with hypertension, it
More information